DeepGreenX Group and Hues Capital Launch $10 Billion USD Fund to Accelerate AI, Green Energy, and Computing Power
New DXG-Hues Fund will target innovative enterprises and solutions in these transformative ecosystems worldwide
DeepGreenX Group Inc. (“DeepGreenX,” “DXG,” or the “Company”), an AI-enabled green energy and technology company, and Hues Capital (“Hues”), a leading capital provider enabling financial technology ecosystems, AI, and green energy enterprises, jointly announced the formation of a new $10 billion USD fund (the “Fund”) to drive global advancements in AI, green energy, and computing power and accelerate sustainability initiatives worldwide.
DeepGreenX and Hues will each hold a 50% stake and act as co-general partners in the $10 billion USD DXG-Hues parent fund, which will be based in the EU and comprise two $5 billion USD sub-funds: the DXG-Hues AI Computing Infrastructure Fund and the DXG-Hues AI Energy Fund. The former will focus on global investments in AI computing power and green energy infrastructure projects, while the latter will target emerging enterprises in the fields of AI ecosystems, fintech, and green energy.
This initiative will bring together seasoned professionals with deep expertise in technology and finance. The Fund’s leadership team will include Miao Wei, former Vice President of Alibaba Cloud, and Dr. Chen Jidong, former Vice President of Ant Group's Digital Technology Division and Chief Product Officer of Security Technology. In connection with the formation of the Fund, Hues founder, Chairman, and Chief Executive Officer Dr. Jim Lai will join the Board of Directors of DeepGreenX.
Dr. Lai was previously Vice President of Tencent, where he led the Financial Internet Technology (FiT) division and contributed to the creation of WeChat Pay, WeChat Red Envelope, and the management of Tencent’s trillion-yuan Wealth Management Platform. He also played a critical role in Tencent's investment strategy, investing into dozens of WeChat Pay ecosystem companies founded by visionary entrepreneurs. He collaborated on incubating and scaling numerous industry-leading unicorns, many of which have gone public, including those focused on AI-driven big data and financial technology, as well as world-leading financial institutions. In his role as a director for several post-investment companies on behalf of Tencent, Dr. Lai has been instrumental in fostering collaboration and synergy within Tencent’s WeChat Pay ecosystem. These companies have also consistently achieved unicorn status, gone public, and generated significant returns for their investors.
“We are thrilled to launch this new Fund with Hues, which is a product of our shared vision that new, innovative capital sources are required for these new, innovative ecosystems. With this collaboration, we are taking a bold and strategic step forward in harnessing AI-driven computing power, advancing sustainable energy solutions, and catalyzing innovative financial systems,” said Barclay Knapp, CEO of DeepGreenX. “We believe this Fund will provide substantial financial resources to high-impact enterprises and projects, accelerating the transition to a global green economy while promoting long-term sustainability.”
DeepGreenX is a rapidly developing international platform company connecting green energy, nature-based and real-world assets (RWA), sustainable computing power, and AI developer communities to new-era digital trading and banking systems. The Company deploys an AI platform-as-a-service (AI PaaS) model to extract and convert sustainability, RWA, and other data into verified digital financial instruments such as renewable energy certificates (REC), tokens, and its own-branded DXG Certificates, which the Company then transacts and monetizes on digital trading and banking systems on behalf of its enterprise clients. Alongside its platform, DeepGreenX is facilitating the synergistic development of human intelligence plus AI applications via a 190,000-person strong AI developer community.
“Hues’ depth of expertise will be instrumental in supporting DeepGreenX’s efforts to establish and operate a global CBDC clearing network,” said Dr. Lai. “This collaboration will also strengthen strategic integration across both companies’ ecosystems, spanning portfolios in AI, green energy, and computing power.”
Hues boasts a foundation of global institutional LPs, with a mission to enable large-scale financial technology ecosystems, AI technology, and green energy enterprises to scale internationally. It seeks to build a globally integrated ecosystem that bridges AI, financial technology, and sustainable energy solutions. It is led by Dr. Lai, former founding Chairman of Fusion Bank, with stakeholders such as Tencent, the Hong Kong Stock Exchange, and ICBC (Asia).
About DeepGreenX
Founded in 2020 and headquartered in Seoul, DeepGreenX Group Inc. is a digital transformation company providing AI and financialization solutions for sustainability initiatives and real-world assets worldwide. With developing operations in 20 cities across four continents, DeepGreenX employs proprietary AI technology and a PaaS model to capture and verify attractive data assets, digitally convert those assets into digital financial products, and then transact with them on global digital trading and banking platforms on behalf of its enterprise customers. For more information on DeepGreenX, visit: www.DeepGreenX.com.
About Hues Capital
Founded in 2023, Hues Capital is a PE fund management company with an internet background, aimed at helping entrepreneurs develop their own companies and businesses in the internet ecosystems of China, Japan, and Southeast Asia. The founder and team of Hues Capital have created the largest mobile payment ecosystem covering the world, incubating and empowering numerous successful unicorn enterprises in the FinTech industry. The current investment areas of Hues Capital mainly include three directions: FinTech, AI, Supercomputing Data Center and New energy EV.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241208029753/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom